nach oben

Erschienen in:

20.05.2022 | Typ-2-Diabetes | DDG Praxisempfehlungen

Adipositas und Diabetes

verfasst von: Prof. Dr. med. Jens Aberle, Anne Lautenbach, Svenja Meyhöfer, Sebastian M. Meyhöfer, Lars Selig, Matthias Blüher, Markus Menzen

Erschienen in: Die Diabetologie | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Auszug

Auf der Webseite der Deutschen Diabetes Gesellschaft (https://www.deutsche-diabetes-gesellschaft.de/behandlung/leitlinien) befinden sich alle PDF zum kostenlosen Download. …

Lindström J, Louheranta A, Mannelin M et al (2003) The Finnish diabetes prevention study (DPS): lifestyle intervention and 3‑year results on diet and physical activity. Diabetes Care 26:3230–3236. https://doi.org/10.2337/diacare.26.12.3230CrossRefPubMed

Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403. https://doi.org/10.1056/NEJMoa012512CrossRefPubMed

Lean MEJ, Powrie JK, Anderson AS et al (1990) Obesity, weight loss and prognosis in type 2 diabetes. Diabet Med 7:228–233. https://doi.org/10.1111/j.1464-5491.1990.tb01375.xCrossRefPubMed

Williamson DF, Thompson TJ, Thun M et al (2000) Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 23:1499–1504. https://doi.org/10.2337/diacare.23.10.1499CrossRefPubMed

Wing RR, Bahnson JL, Bray GA et al (2010) Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the look AHEAD trial. Arch Intern Med 170:1566–1575. https://doi.org/10.1001/archinternmed.2010.334CrossRefPubMed

Eeg-Olofsson K, Cederholm J, Nilsson PM et al (2009) Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. Diabetologia 52:65–73. https://doi.org/10.1007/s00125-008-1190-xCrossRefPubMed

Buse JB, Wexler DJ, Tsapas A et al (2020) 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care 43:487–493. https://doi.org/10.2337/dci19-0066CrossRefPubMed

Wang Z, Hoy WE (2004) Waist circumference, body mass index, hip circumference and waist-to-hip ratio as predictors of cardiovascular disease in Aboriginal people. Eur J Clin Nutr 58:888–893. https://doi.org/10.1038/sj.ejcn.1601891CrossRefPubMed

Pischon T, Boeing H, Hoffmann K et al (2008) General and abdominal adiposity and risk of death in Europe. N Engl J Med 359:2105–2120. https://doi.org/10.1056/NEJMoa0801891CrossRefPubMed

10.

Evert AB, Dennison M, Gardner CD et al (2019) Nutrition therapy for adults with diabetes or prediabetes: a consensus report. Diabetes Care 42:731–754. https://doi.org/10.2337/dci19-0014CrossRefPubMedPubMedCentral

11.

Reynolds AN, Akerman AP, Mann J (2020) Dietary fibre and whole grains in diabetes management: systematic review and meta-analyses. PLoS Med 17:e1003053. https://doi.org/10.1371/journal.pmed.1003053CrossRefPubMedPubMedCentral

12.

Landgraf R, Aberle J, Birkenfeld AL et al (2019) Therapy of type 2 diabetes. Exp Clin Endocrinol Diabetes 127:S73–S92. https://doi.org/10.1055/a-1018-9106CrossRefPubMed

13.

Lean ME, Leslie WS, Barnes AC et al (2018) Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 391:541–551. https://doi.org/10.1016/S0140-6736(17)33102-1CrossRefPubMed

14.

Gregg EW, Chen H, Wagenknecht LE et al (2012) Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA 308:2489–2496. https://doi.org/10.1001/jama.2012.67929CrossRefPubMedPubMedCentral

15.

Nationale VersorgungsLeitlinie Diabetes, 1. Aufl.

16.

Kay SJ, Fiatarone Singh MA (2006) The influence of physical activity on abdominal fat: a systematic review of the literature. Obes Rev 7:183–200. https://doi.org/10.1111/j.1467-789X.2006.00250.xCrossRefPubMed

17.

Piercy KL, Troiano RP, Ballard RM et al (2018) The physical activity guidelines for Americans. JAMA 320:2020. https://doi.org/10.1001/jama.2018.14854CrossRefPubMed

18.

Vilsbøll T, Christensen M, Junker AE et al (2012) Effects of glucagon-like peptide‑1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. https://doi.org/10.1136/bmj.d7771CrossRefPubMedPubMedCentral

19.

Pi-Sunyer X, Astrup A, Fujioka K et al (2015) A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 373:11–22. https://doi.org/10.1056/nejmoa1411892CrossRefPubMed

20.

Wilding JPH, Batterham RL, Calanna S et al (2021) Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 384:989–1002. https://doi.org/10.1056/nejmoa2032183CrossRefPubMed

21.

Muscelli E, Mari A, Casolaro A et al (2008) Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 57:1340–1348. https://doi.org/10.2337/db07-1315CrossRefPubMed

22.

Liu C, Li C, Cai X et al (2021) Discovery of a novel GLP-1/GIP dual receptor agonist CY‑5 as long-acting hypoglycemic, anti-obesity agent. Bioorg Chem. https://doi.org/10.1016/j.bioorg.2020.104492CrossRefPubMedPubMedCentral

23.

Gautier JF, Choukem SP, Girard J (2008) Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab. https://doi.org/10.1016/S1262-3636(08)73397-4CrossRefPubMed

24.

Alvarez E, Martínez MD, Roncero I et al (2005) The expression of GLP‑1 receptor mRNA and protein allows the effect of GLP‑1 on glucose metabolism in the human hypothalamus and brainstem. J Neurochem 92:798–806. https://doi.org/10.1111/j.1471-4159.2004.02914.xCrossRefPubMed

25.

Rosenstock J, Wysham C, Frías JP et al (2021) Efficacy and safety of a novel dual GIP and GLP‑1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. https://doi.org/10.1016/S0140-6736(21)01324-6CrossRefPubMed

26.

Rubino F, Nathan DM, Eckel RH et al (2016) Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care 39:861–877. https://doi.org/10.2337/dc16-0236CrossRefPubMed

27.

AWMF online (2018) S3-Leitlinie: Chirurgie der Adipositas und metabolischer Erkrankungen (Version 2.3)

28.

Longitudinal Assessment of Bariatric Surgery (LABS) Consortium et al (2009) Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 361:445–454. https://doi.org/10.1056/nejmoa0901836CrossRef

29.

Birkmeyer NJO, Dimick JB, Share D et al (2010) Hospital complication rates with bariatric surgery in Michigan. JAMA 304:435–442. https://doi.org/10.1001/jama.2010.1034CrossRefPubMed

30.

Aberle J, Reining F, Dannheim V et al (2012) Metformin after bariatric surgery—an acid problem. Exp Clin Endocrinol Diabetes 120:152–153. https://doi.org/10.1055/s-0031-1285911CrossRefPubMed

31.

Dungan KM, Povedano ST, Forst T et al (2014) Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type BROWN ET AL. 9 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet 384(9951):1349–1357CrossRef

32.

Buse JB, Drucker DJ, Taylor KL et al (2010) DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 33(6):1255–1261CrossRef

33.

Buse JB, Rosenstock J, Sesti G et al (2009) Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374(9683):39–47CrossRef

34.

Buse JB, Nauck M, Forst T et al (2013) Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 381(9861):117–124CrossRef

35.

Kanters S, Wilkinson L, Vrazic H et al (2019) Comparative efficacy of once-weekly semaglutide versus SGLT‑2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis. BMJ Open 9(7):e23458. https://doi.org/10.1136/bmjopen-2018-023458CrossRefPubMedPubMedCentral

36.

Stenlöf K, Cefalu WT, Kim KA et al (2013) Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 15(4):372–382CrossRef

37.

Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF (2010) Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 33(10):2217–2224CrossRef

38.

Haring HU, Merker L, Seewaldt-Becker E et al (2014) Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 37(6):1650–1659CrossRef

39.

Rosenstock J, Frias J, Pall D et al (2018) Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab 20(3):520–529CrossRef

Titel: Adipositas und Diabetes
verfasst von: Prof. Dr. med. Jens Aberle
Anne Lautenbach
Svenja Meyhöfer
Sebastian M. Meyhöfer
Lars Selig
Matthias Blüher
Markus Menzen
Publikationsdatum: 20.05.2022
Verlag: Springer Medizin
Schlagwörter: Typ-2-Diabetes
Adipositas
Bariatrische Chirurgie
Adipositas
Metformin
Bariatrische Chirurgie
Erschienen in: Die Diabetologie / Ausgabe 4/2022
Print ISSN: 2731-7447
Elektronische ISSN: 2731-7455
DOI: https://doi.org/10.1007/s11428-022-00903-7

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft.

Zu den Praxisempfehlungen

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2022

Diabetes im Krankenhaus

Mitteilungen des BDI

Prävalenz eines Vitamin-B12-Mangels bei Metformintherapie

DDG Praxisempfehlungen: Lipidtherapie bei Patienten mit Diabetes mellitus

Leitlinien in der Diabetologie – Bedeutung im Praxisalltag und in der Gesundheitspolitik

Stationäre Patienten mit der Nebendiagnose Diabetes mellitus: klinische Relevanz

Praxisempfehlungen der Deutschen Diabetes Gesellschaft